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Research over the last few years has demonstrated the increasing role of microRNAs (miRNAs) as major
regulators of gene expression in diverse cellular processes and diseases. Several viruses, particularly herpes-
viruses, also use the miRNA pathway of gene regulation by encoding their own miRNAs. Marek’s disease (MD)
is a widespread lymphomatous neoplastic disease of poultry caused by the highly contagious Marek’s disease
virus type 1 (MDV-1). Recent studies using virus-infected chicken embryo fibroblasts have identified at least
eight miRNAs that map to the RL/RS region of the MDV genome. Since MDV is a lymphotropic virus that
induces T-cell lymphomas, analysis of the miRNA profile in T-cell lymphoma would be more relevant for
examining their role in oncogenesis. We determined the viral and host miRNAs expressed in MSB-1, a
lymphoblastoid cell line established from an MDV-induced lymphoma of the spleen. In this paper, we report
the identification of 13 MDV-1-encoded miRNAs (12 by direct cloning and 1 by Northern blotting) from MSB-1
cells. These miRNAs, five of which are novel MDV-1 miRNAs, map to the Meq and latency-associated
transcript regions of the MDV genome. Furthermore, we show that miRNAs encoded by MDV-1 and the
coinfected MDV-2 accounted for >60% of the 5,099 sequences of the MSB-1 “miRNAome.” Several chicken
miRNAs, some of which are known to be associated with cancer, were also cloned from MSB-1 cells. High levels
of expression of MDV-1-encoded miRNAs and potentially oncogenic host miRNAs suggest that miRNAs may
have major roles in MDV pathogenesis and neoplastic transformation.
Marek’s disease (MD) is a naturally occurring rapid-onset
aggressive T-cell lymphoma of poultry. Named after the Hun-
garian veterinarian Jos´zef Marek, who first reported the dis-
ease in 1907 (41), the disease is induced by Marek’s disease
virus type 1 (MDV-1), a highly contagious alphaherpesvirus
belonging to the genus Mardivirus of the family Herpesviridae
(31). Apart from being a major disease affecting poultry health
and welfare, MD is considered to be an excellent biomedical
model for virus-induced lymphoma (7, 14). Among the 100-
plus genes predicted for the MDV genome (40, 47, 48), the
gene for the basic leucine zipper protein Meq is considered to
be the major oncogene (39, 44). Some of the functions of Meq
associated with oncogenic properties, such as its interaction
with CtBP, parallel those of other viral oncogenic sequences,
such as adenovirus E1A and Epstein-Barr virus (EBV) nuclear
antigens EBNA3A and -3C (6), highlighting the convergent
evolution of oncogenic pathways in these viruses. Recent stud-
ies have also identified the role of other genes, such as the pp38
(23), viral interleukin-8 (vIL-8) (49), ICP4 (15, 38), R-LORF4
(33), UL36 (32), and MDV-encoded telomerase RNA (22, 63)
genes, in pathogenesis.
Increasing evidence demonstrates that in addition to the
direct role of protein-encoding genes, noncoding RNAs have
profound effects in mediating neoplastic transformation (13).
Among these, the 22-nucleotide microRNAs (miRNAs) have
emerged as a major regulatory tier of gene expression, with the
potential of targeting up to 30% of genes in humans (17, 27,
37). Given their small size with the capability for regulating
multiple genes, several viruses have adopted the miRNA ma-
chinery to manipulate the cellular and viral pathways of gene
regulation by encoding their own miRNAs (19, 24, 26, 42).
Among the different families of viruses, herpesviruses have
exploited the miRNA-mediated gene regulation pathway most
successfully, since 124 of the 127 virus-encoded miRNAs in
miRBase release 10.1 (http://microrna.sanger.ac.uk) are en-
coded by herpesviruses. It has been suggested that the
miRNA-mediated regulatory mechanisms are very suited for
the herpesvirus life cycle, which is characterized by nuclear
replication and latent periods with minimal antigen expression
(19).
Specific miRNA signatures in different types of tumors have
been identified using high-throughput microarray analysis of
miRNA expression (60, 64, 67). Considering the aggressive
nature and rapid onset of tumors induced by MDV-1, analysis
of the miRNA profile of MDV-transformed tumor cells could
provide further insights into MD oncogenesis. Previous studies
using small RNAs from MDV-infected chicken embryo fibro-
blasts (CEF) have identified several miRNAs, including eight
MDV-encoded miRNAs that mapped to the Meq and the
latency-associated transcript (LAT) region of the genome (8,
9). Although identification of MDV and host miRNAs in lyti-
cally infected CEF is valuable, understanding the expression
profiles of miRNAs in the lymphocyte target cells of MD
lymphomas would be crucial to delineate their role in neoplas-
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tic transformation. Primary MD lymphomas are often hetero-
geneous mixtures of neoplastic T cells and nontransformed
cells of other lineages (50), so analysis of the whole tumor may
not provide the miRNA profile of the transformed target cell.
However, the ability to establish homogeneous clonal popula-
tions of lymphoblastoid cell lines from primary tumors has
helped to gain insights into the gene expression profiles of MD
tumor cells (10). We reasoned that examination of the miRNA
profiles of MDV-transformed lymphoblastoid cell lines could
help to analyze their roles in neoplastic transformation and in
the maintenance of MDV latency in target T cells.
MSB-1 is an MDV-transformed CD4 T-cell line derived
from a spleen lymphoma induced by the BC-1 strain of MDV-1
(1, 30). The MSB-1 cell line, used in this study at passage level
13, has a CD4 phenotype and has been shown to be coin-
fected with MDV-1 and MDV-2 (66). The MSB-1 cell line has
both integrated and circular copies of the MDV-1 genome (56)
and induces tumors when it is inoculated into susceptible
TABLE 1. Sequences, chromosomal locations, and cloning frequencies of chicken miRNAs cloned from an MSB-1 library
Namea Sequence No. of hitsin library
Chromosomal
location
Start
position
End
position
gga-mir-7 TGGAAGACTAGTGATTTTGTTG 3 Z_random 12717978 12718086
gga-mir-15a TAGCAGCACATAATGGTTTGT 28 1 161540787 161540869
gga-mir-15b TAGCAGCACATCATGGTTTGCA 9 9 21649291 21649381
1 161540645 161540728
gga-mir-16 TAGCAGCACGTAAATATTGGTG 82 9 21649116 21649209
gga-mir-17-5p CAAAGTGCTTACAGTGCAGGTAA 55 1 140631124 140631208
gga-mir-18a TAAGGTGCATCTAGTGCAGATA 10 1 140630969 140631061
gga-mir-18b TAAGGTGCATCTAGTGCAGTTA 10 4 3781954 3782037
gga-mir-19a TGTGCAAATCTATGCAAAACTGA 71 1 140630835 140630915
gga-mir-19b TGTGCAAATCCATGCAAAACTGA 71 1 140630526 140630612
gga-mir-20a TAAAGTGCTTATAGTGCAGGTAG 18 1 140630649 140630746
gga-mir-20b CAAAGTGCTCATAGTGCAGGTAG 16 4 3781773 3781857
gga-mir-21 TAGCTTATCAGACTGATGTTGA 249 19 6933581 6933677
gga-mir-23b ATCACATTGCCAGGGATTAC 2 Z_random 14203199 14203284
gga-mir-24 TGGCTCAGTTCAGCAGGAACAG 6 Z_random 14203968 14204035
gga-mir-26a TTCAAGTAATCCAGGATAGGC 14 2 4034213 4034289
gga-mir-27b TTCACAGTGGCTAAGTTCTGC 10 Z_random 14203435 14203531
26 1280249 1280328
gga-mir-29b TAGCACCATTTGAAATCAGTGTT 98 1 204569 204649
gga-mir-30b TGTAAACATCCTACACTCAGCT 1 2 141145952 141146038
3 80699454 80699525
gga-mir-30c TGTAAACATCCTACACTCTCAGCT 1 23 4431115 4431203
gga-mir-30d TGTAAACATCCCCGACTGGAAGC 16 2 141142201 141142264
gga-mir-30a-5p TGTAAACATCCTCGACTGGAAGCT 13 3 80674840 80674911
gga-mir-33 GTGCATTGTAGTTGCATTG 6 1 46203134 46203202
gga-mir-34a TGGCAGTGTCTTAGCTGGTTGTT 7 21 3118925 3119033
gga-miR-92 TATTGCACTTGTCCCGGCCTGT 9 1 140630413 140630490
gga-mir-101 TACAGTACTGTGATAACTGAAG 9 Z 11651019 11651097
gga-mir-106 AAAAGTGCTTACAGTGCAGGTA 55 4 3782085 3782165
gga-mir-130a CAGTGCAATATTAAAAGGGCA 4 15 393029 393111
gga-mir-140 AGTGGTTTTACCCTATGGTAG 5 11_random 250924 251018
gga-mir-142-3p TGTAGTGTTTCCTACTTTATGGA 224 Un 130069949 130070036
gga-mir-142-5p CCCATAAAGTAGAAAGCACTAC 243 Un 130069949 130070036
gga-mir-146b TGAGAACTGAATTCCATAGGCG 44 6 22212586 22212690
gga-mir-181a AACATTCAACGCTGTCGGTGAGTT 5 8 1957561 1957664
17 945791 945881
8 1957750 1957838
gga-mir-181b AACATTCATTGCTGTCGGTGGGTTT 6 17 944157 944241
gga-mir-221 AGCTACATTGTCTGCTGGGTTTC 11 1 104369325 104369423
gga-mir-222 AGCTACATCTGGCTACTGGGT 7 1 104368821 104368918
gga-mir-301 CAGTGCAATAATATTGTCAAAGCATT 3 15 391803 391895
gga-mir-456 CAGGCTGGTTAGATGGTTGTCCT 4 3 27735429 27735540
gga-let-7i TGAGGTAGTAGTTTGTGCTGT 148 1 29988296 29988379
12 6149732 6149821
gga-let-7a TGAGGTAGTAGGTTGTATAGTT 12 24 3263054 3263125
1 67795667 67795742
gga-mir-363* AATTGCACGGTATCCATCTGTA 30
gga-mir-454* TAGTGCAATATTGCTTATAGGGT 5
gga-mir-425* AATGACACGATCACTCCCGTTGA 6
gga-mir-191* CAACGGAATCCCAAAAGCAGCTG 8
gga-mir-22* AAGCTGCCAGTTGAAGAACTGT 6
gga-mir-739* AAGGCCGAAGTGGAGAAGGGTTCCA 1
a *, novel miRNAs identified in chickens and assigned names on the basis of homology to miRNAs in other species.
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chickens (21, 35). As reported for some MD tumors, these cells
also showed truncated forms of p53 tumor suppressor protein
(62). Northern blot analysis of the expression of MDV-induced
miRNAs in MSB-1 cells showed that many of the miRNAs are
expressed at much higher levels than those in infected CEF (8,
9). These results demonstrate that the MSB-1 lymphoblastoid
cell line, which shares many properties of MD tumors, could be
used as a model system for analyzing the molecular pathways
and mechanisms of neoplastic transformation in MD tumors.
We recently reported the construction of a library, using small
RNAs fractionated from MSB-1 cells, to identify novel MDV-
2-encoded miRNAs (66). In this paper, we describe the results
of analysis of the MSB-1 “miRNAome” to examine the popu-
lation of host and viral miRNAs expressed in this transformed
cell line.
MATERIALS AND METHODS
Cells and viruses. CEF prepared from 10-day-old specific-pathogen-free em-
bryos obtained from flocks maintained at the Institute for Animal Health were
used for the propagation of viruses. Low-passage-number virus stocks of RB-1B
(58) grown in CEF for 72 to 96 h were used for the preparation of RNA for
Northern blotting analysis. The MDV-transformed lymphoblastoid cell line
MSB-1 (1) and the REV-T-transformed (16) chicken CD4 T-cell line AVOL-1
were grown at 38.5°C in 5% CO2 in RPMI 1640 medium containing 10% fetal
calf serum, 10% tryptose phosphate broth, and 1% sodium pyruvate.
Cloning and identification of miRNAs. We have previously described the
construction of a cDNA library from small RNAs prepared from MSB-1 cells
(66). Concatemerized sequences of putative miRNAs from the pGEM-T Easy
(Promega, Southampton, United Kingdom) library were determined using vec-
tor-specific primers. High-quality reads of small RNA sequences with both 5 and
3 adapters were analyzed for the characterization of miRNAs.
Northern blotting analysis. Total RNA was extracted from cultured cells by
using TRIzol reagent (Invitrogen) according to standard methods described by
the manufacturer. RNAs were also isolated from samples of MD lymphomas as
well as from livers, brains, hearts, kidneys, ovaries, lungs, thymuses, and spleens
of uninfected adult chickens, using TRIzol reagent. Samples of 20 g total RNA
were resolved in a 15% polyacrylamide-urea gel and blotted onto a GeneScreen
Plus membrane (Perkin-Elmer). DNA oligonucleotides with the exact comple-
mentary sequence to selected miRNAs were end labeled with [-32P]ATP by use
of T4 polynucleotide kinase (New England Biolabs, Hertfordshire, United King-
dom) to generate high-specific-activity probes. Hybridization, washing, and au-
toradiography were carried out as previously described (36, 53).
RESULTS
Identification of miRNAs expressed in MSB-1 cells. The
MDV-transformed lymphoblastoid T-cell line MSB-1 has been
used extensively in different laboratories for various studies,
particularly for the analysis of MDV latency programs (43). As
a tumor cell line latently infected with MDV-1, we chose
MSB-1 to analyze the miRNA profile of MD tumor cells.
Sequence analysis of 1,200 pGEM-T Easy clones of cDNA
concatemers of small RNA sequences from the MSB-1 library
identified a total of 5,099 high-quality reads. The sequences
were scored as miRNAs on the basis that their flanking se-
quences could be predicted into a stem-loop structure with low
free energyBlast (2). Homology searches of these sequences
against the miRBase (25) and GenBank (5) databases were
used to determine the identities of the different host- and
virus-encoded small RNAs. Of the total reads, 1,641 (32.2%)
matched known Gallus gallus miRNAs in the miRBase. The
most abundant host miRNAs in the MSB-1 library were gga-
miR-21, gga-miR-142-3p, gga-miR-142-5p, gga-let-7i, gga-
miR-29b, gga-miR-16 gga-miR-17-5p, gga-miR-19a, gga-miR-
19b, gga-miR-106, and gga-miR-146b. Sequence analysis of the
clones from the MSB-1 library also identified six novel chicken
miRNAs, which appeared to be homologs of hsa-miR-363,
hsa-miR-454-3p, hsa-miR-425-5p, bta-miR-191, hsa-miR-22,
and dre-miR-739. The number of reads of each host-encoded
miRNA in the library and their chromosomal locations are
shown in Table 1. In addition to these miRNAs and the virus-
encoded miRNAs (see below), 128 (2.5%) were noncoding
TABLE 2. Sequences and genomic positions of MDV-1 miRNAsa
Name Sequence (5 to 3) Length (nt) No. of hits Nucleotide positionb
MDV1-miR-M1-5p UGCUUGUUCACUGUGCGGCA(UUAU) 20–24 339 136873–136896
MDV1-miR-M1-3p (A)UGCUGCGCAUGAAAGAGCGA(A) 21–23 4 136913–136934
MDV1-miR-M2-5p (G)UUGUAUUCUGCCCGGUAGUCC(GUUU) 22–26 16 134231–134256
MDV1-miR-M2-3p (A)CGGACUGCCGCAGAAUAGC(UUU) 19–22 11 134270–134292
MDV1-miR-M3-5p (CAUG)AAAAUGUGAAACCUCUC(CCGCU) 20–25 390 134079–134104
MDV1-miR-M4-5p (UUUAA)UGCUGUAUCGGAACC(CUUCGUU) 19–26 341 134367–134393
MDV1-miR-M4-3p (CGA)AUGGUUCUGACAGCAUGAC(CU) 20–22 50 134403–134426
MDV1-miR-M5-5p AACCGUAUGCGAUCACAUUGAC 22 0 133606–133628
MDV1-miR-M5-3p (U)GUGUAUCGUGGUCGUCUACU(GUU) 21–24 176 133647–133670
MDV1-miR-M6-5p (UCU)GUUGUUCCGUAGUGUUC(UC) 18–22 278 142335–142356
MDV1-miR-M6-3p (GAG)AUCCCUGCGAAAUGACAGU(U) 19–23 14 142370–142392
MDV1-miR-M7-5p (UGU)UAUCUCGGGGAGAUCCC(GAU) 19–23 800 142508–142530
MDV1-miR-M8-5p UAUUGUUCUGUGGUUGGUUUC(GA) 21–23 18 142216–142238
MDV1-miR-M8-3p (GU)GACCUCUACGGAACAAUAG(U) 20–22 36 142258–142279
MDV1-miR-M9-5p UUUUCUCCUUCCCCCCGGAGUU(CA) 22–24 45 133374–133397
MDV1-miR-M9-3p AAACUCCGAGGGCAGGAAAAAG 22 1 133414–133435
MDV1-miR-M10-3p (UCG)AAAUCUCUACGAGAUAACA(GU) 20–23 6 142667–142690
MDV1-miR-M11-5p UUUUCCUUACCGUGUAGCUUAGA 23 2 136053–136075
MDV1-miR-M11-3p UGAGUUACAUGGUCAGGGGAUU 22 0 136092–136113
MDV1-miR-M12-3p (U)UGCAUAAUACGGAGGGUUCU(G) 21–22 35 133925–133946
MDV1-miR-13-3p GCAUGGAAACGUCCUGGGAAA 21 0 142313–142333
a Sequence variation surrounding the recovered BC-1 miRNAs is indicated by parentheses surrounding the variable nucleotides. miRNAs derived from a single
primary miRNA stem-loop precursor are indicated by a “-5p” (5 arm) or “-3p” (3 arm) suffix.
b Based on the Md5 sequence (GenBank accession no. AF243438).
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RNA fragments, 76 (1.5%) were mRNA fragments, and 174
(3.4%) showed no matches to any known RNAs.
For the identification of the virus-encoded miRNAs, BLAST
searches were carried out against the full-length sequences of
MDV-1 (Md5 strain; GenBank accession number AF243438)
and MDV-2 (HPRS-24 strain; GenBank accession number
AB049735). We have previously shown that 518 (10.2%) se-
quences from the MSB-1 library are encoded by MDV-2 (66).
However, the majority of the 2,562 (50.2%) sequences from
this library showed perfect sequence identity to the genome
sequence of the Md5 strain. These miRNA sequences, ranging
in length from 18 to 26 nucleotides, belonged to 12 distinct
MDV-1-encoded miRNAs. These included the eight miRNAs
(mdv-miR-M1 to -M8) identified previously from MDV-infected
CEF cultures (8) and four novel MDV-1-encoded miRNAs
(mdv-miR-M9 to -M12). Additionally, we identified another
novel miRNA, mdv-miR-M13, using Northern blotting analysis
of RNAs extracted from MSB-1 cells (see below). The genomic
location and cloning frequency of each of the MDV-1-encoded
miRNAs are shown in Table 2.
MDV-1 miRNAs fold into distinct hairpin structures. For
the validation of a sequence as a miRNA, demonstration of its
expression as well as its processing through the miRNA bio-
genesis pathway is required. One of the distinct indicators of
miRNA biogenesis is the presence of adjacent complementary
sequences that are able to form stable hairpins. In order to
analyze the potential precursor structures of miRNAs encoded
by MDV-1, the sequences of the 13 miRNAs with their adja-
cent 60 to 80 nucleotides were analyzed by MFOLD calcula-
tion, and the secondary structures were drawn using
RNADRAW software as described previously (66). All of the
MDV-1 miRNAs showed a stable hairpin with long paired
stems (Fig. 1), indicating that they are bona fide miRNAs. Of
the two strands of the miRNA duplex generated during bio-
genesis, only one of the strands, the miRNA strand, is incor-
porated into the RNA-induced silencing complex and guides
gene regulation (3). Although the non-miRNA strand is rap-
idly degraded, in many instances it is also captured during
cloning and may sometimes be detected with a comparable
frequency to that of the miRNA strand (66). Among the
MDV-1 miRNAs in MSB-1 cells, two mature forms, represent-
ing both strands of the duplex, were demonstrated by cloning
or Northern blotting for 8 of the 13 candidate miRNAs, in-
creasing the total number of miRNAs to 21. The suffixes “-5p”
and “-3p” were added to designations to indicate the 5 and 3
arms, respectively, of the stem-loop precursor from which the
miRNAs were derived (Table 2).
MDV-1 miRNAs show differences in cloning frequencies.
We then examined the cloning frequency of each of the
MDV-1 miRNAs as a measure of their expression levels in
MSB-1 cells. The most abundantly cloned miRNAs were mdv-
miR-M7-5p (800 hits), mdv-miR-M3-5p (390 hits), mdv-miR-
M4-5p (341 hits), mdv-miR-M1-5p (339 hits), mdv-miR-M6-5p
(278 hits), and mdv-miR-M5-3p (176 hits). Compared to this,
mdv-miR-M10, -M11, and -M13 were of very low abundance,
while mdv-miR-M2, -M8, -M9, and -M12 showed moderate
copy numbers in the library. For most miRNAs, the non-
miRNA strand of the duplex was either not cloned or had a
relative frequency much lower than that of the miRNA strand.
However, for some of the miRNAs, such as mdv-miR-M2, the
FIG. 1. Secondary structures of MDV-1 pre-miRNAs predicted us-
ing the MFOLD algorithm (68). The mature miRNA strands are
indicated in red.
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frequencies of both strands were very similar, suggesting that
both may be functional and are incorporated into the RNA-
induced silencing complex.
MDV-1 miRNAs are clustered in the repeat regions of the
MDV-1 genome. The nucleotide sequence positions of the dif-
ferent miRNAs are shown in Table 2. All 13 MDV-1-encoded
miRNAs are clustered in an 9-kb region within the RL/RS
sequences of the MDV genome (Fig. 2). The miRNAs mdv-
miR-M2, -M3, -M4, -M5, -M9, and -M12 are located upstream
of Meq and are antisense to the R-LORF8 transcript. The
miRNAs mdv-miR-M1 and -M11 lie downstream of Meq and
are embedded within the open reading frame (ORF) of the
L1/LORF5a transcript (46, 59) as well as within the intron of
the splice variant Meq-sp (51). MDV-1-encoded miRNAs
mdv-miR-M6, -M7, -M8, -M10, and -M13 are located between
the a-like sequence and the ICP4 sequence within the large
intron of the LAT of MSR (15). Of this cluster, the miRNAs
mdv-miR-M6 and mdv-miR-M13 were separated by only a
single nucleotide. The occurrence of the miRNAs in distinct
clusters in the same orientation strongly suggests that these
miRNAs are likely to be processed as multicistronic pre-
miRNA transcripts. Despite being processed from a single
transcript, there are differences in the expression levels of the
mature miRNAs, and these are thought to be due to differ-
ences in Drosha processing and/or miRNA stability.
Analysis of miRNA expression by Northern blotting. For
further confirmation of the expression of miRNAs in MSB-1
cells, Northern blot hybridization with individual MDV-1
miRNA probes was carried out on RNAs extracted from
MSB-1, AVOL-1 (an MDV-negative T-cell line), or uninfected
or RB-1B virus-infected CEF cells and from samples of MD
lymphoma. These studies confirmed that MDV-1-encoded
miRNAs are expressed at high levels in MSB-1 cells and MD
lymphomas and at low levels in infected CEF (Fig. 3). No
signals were obtained from the RNAs extracted from AVOL-1
cells and uninfected CEF, validating the specificity of the
miRNA probes. Based on the intensities of signals, the levels
of expression of the majority of miRNAs were similar in both
MSB-1 cells and lymphoma samples. Some of the most abun-
dantly cloned miRNAs, such as mdv-miR-M3, -M4, -M5, -M6,
and -M7, showed very strong signals by Northern blotting,
validating the correlation between cloning frequency and ex-
pression level. Similarly, mdv-miR-M10, -M11, and -M13,
cloned at very low frequencies from the library, gave weak
signals by Northern blotting. A previous study using Northern
blotting of RNAs extracted from MD lymphomas reported
that mdv-miR-M6 is expressed at low levels, and mdv-miR-M7
was not detected at all (8). However, our studies using probes
specific for the mdv-miR-M6-5p and mdv-miR-M7-5p strands
gave strong signals for all samples, including MD lymphomas,
indicating that the -5p strand of the duplex is the functional
miRNA strand. The failure to detect these miRNAs in North-
ern blots in the previous study was likely due to the use of the
non-miRNA strand as the probe. In most cases, both pre-
miRNAs and mature miRNAs could be detected by Northern
blotting, with the former giving much lower signals. For some
of the miRNAs, such as mdv-miR-M5-5p, mdv-miR-M9-3p,
and mdv-miR-M13, the signals of pre-miRNAs were higher
than those of the mature miRNAs, indicating less efficient
processing.
Northern blotting was also carried out on RNAs extracted
from eight different normal tissues from adult noninfected
chickens to validate the expression of some of the miRNAs
cloned from the MSB-1 library. Some of these miRNAs, in-
cluding novel chicken miRNAs such as gga-miR-363, gga-miR-
454 gga-miR-425, gga-miR-191, and gga-miR-22, could be de-
tected by Northern blot analysis, albeit with differences in
expression levels between tissues (Fig. 3b). While gga-miR-425
and gga-miR-22 showed high levels of expression in all tissues,
gga-miR-454 was detected at very low levels. The expression of
the miRNAs gga-miR-191, gga-miR-363, and gga-miR-425 in
lymphoid organs, namely, the spleen, thymus, and the lungs
(55), was at the levels observed for the lymphocyte-specific
miRNA gga-miR-142 (54, 65), which gave strong signals with
probes specific for either of the strands of the duplex in these
tissues.
DISCUSSION
As efficient inducers of cancer, oncogenic viruses have
helped to reveal several major pathways of oncogenesis. Most
of these pathways involve the interactions of virus-encoded
oncoproteins, such as simian virus 40 T antigen, adenovirus
E1A, human papillomavirus E6/E7, and EBV EBNAs (69). In
MD tumors, MDV-encoded Meq is considered to be the major
oncoprotein (39), although other proteins also contribute to
oncogenesis (44). The discovery of virus-encoded miRNAs in
several oncogenic viruses (53) has added yet another armory to
FIG. 2. Genomic locations of MDV-1 miRNAs. The schematic diagram shows where the MDV-1 miRNAs (small arrowheads) identified in this
report map. The five novel miRNAs identified in this report are shown in bold. The TRL and IRL regions flanking the unique long region and the
TRS and IRS regions flanking the unique short regions are shown. Genomic positions and orientations of MDV ORFs contained in the miRNA
loci are indicated.
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these viruses for regulating gene expression in cancer cells.
Recent studies on small RNAs from infected CEF have iden-
tified eight MDV-1-encoded miRNAs that map to the Meq
and LAT regions of the genome (8, 9). Furthermore, several
recent studies have identified specific miRNA signatures in
different tumors, providing insights into the different onco-
genic pathways in these tumors (20, 64). In order to analyze the
expression profiles of the host- and MDV-1-encoded miRNAs
in MD tumor cells, we examined the miRNAs expressed in the
MDV-transformed lymphoblastoid cell line MSB-1 by cloning
and Northern blot analysis.
One of the conspicuous findings from the analysis of the
miRNA sequences from the MSB-1 library was the very large
proportion of MDV-1-encoded miRNAs (51%) in relation to
the number of host miRNAs (Fig. 4). This level of expression
of MDV-1 miRNAs is much higher than that identified from
MDV-1-infected CEF, where only 0.6% of the nearly 172,000
reads were miRNAs encoded by MDV-1 (9). The low level of
expression of MDV-1 miRNAs in CEF (also evident from the
results of the Northern blotting analysis) could partly be ex-
plained by the smaller proportions of infected cells in CEF
cultures in comparison to MSB-1 cell cultures, where each cell
has multiple copies of the MDV genome. However, the in-
creased expression of MDV-1 miRNAs in MSB-1 cells may
also be related to the increased lymphocyte-specific expression
of these miRNAs in these transformed target cells. An in-
creased proportion of virus-encoded miRNAs over host-en-
coded miRNAs is not uncommon in transformed cell lines. For
example, miRNAs encoded by Kaposi’s sarcoma-associated
herpesvirus and EBV accounted for 40% of the entire
miRNA pool identified from the BC-1 cell line coinfected with
these two viruses (11). Once the 518 (10%) MDV-2-encoded
miRNAs that we reported previously (66) were also consid-
ered, the total proportion of virus-encoded miRNAs in the
MSB-1 library was 61%, compared to the 32.2% expression of
host-encoded miRNAs. The reasons for the fivefold difference
in the levels of miRNAs encoded by the two viruses are not
known but may be connected with the differences in relative
copy numbers of the two viruses. The precise copy numbers or
replication rates of the two viruses in MSB-1 cells are not
known. However, on CEF cocultivated with MSB-1 cells,
MDV-2 produced 10-fold more plaques than did MDV-1, sug-
gesting that MDV-2 is better adapted for faster replication on
CEF (66).
Previous studies of MDV-1-infected CEF identified eight
miRNAs that mapped to the Meq and LAT regions of the
MDV genome (8, 9). We also cloned all eight of these miRNAs
from the MSB-1 library. However, we also identified 5 new
MDV-1 miRNAs, taking the total number of MDV-1-encoded
miRNAs to 13. As in the case of the eight previously identified
miRNAs, the five new MDV-1 miRNAs mapped to the Meq
and LAT regions of the genome (Fig. 2). In the MDV genome,
FIG. 3. (a) Northern blotting analysis for determining the expres-
sion of MDV-1 miRNAs. Twenty micrograms of total RNA from
MSB-1 cells, the MDV-negative lymphoid cell line AVOL-1, MDV-1-
infected CEF, uninfected CEF, or MD lymphoma tissues was sepa-
rated in a 15% denaturing polyacrylamide gel, blotted, and probed
with end-labeled antisense oligonucleotides to the indicated miRNAs.
Size markers to indicate the positions of the pre-miRNA and the
mature miRNA are shown. The cellular U6 snRNA served as the
loading control, and a representative blot of this set is shown. (b)
Analysis of tissue-specific expression of Gallus gallus (gga-) miRNAs
identified in the MSB-1 library. Total RNAs (20 g) extracted from
different tissues of chickens were separated in polyacrylamide gels and
probed with end-labeled antisense oligonucleotides specific for the
individual miRNAs indicated. The cellular U6 snRNA served as the
loading control.
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while most of the genes are transcriptionally silent in latently
infected and tumor cells, the repeat (RL/RS) regions are gen-
erally active (34, 45, 61). Thus, it is not surprising that all of the
miRNAs that are expressed at high levels in latently infected/
tumor cells are located in a transcriptionally active region of
the genome. The genomic locations of the eight previously
reported MDV-1-encoded miRNAs have been described (8,
9). Two of the new miRNAs, mdv-miR-M9 and mdv-miR-
M12, are also located upstream of the Meq promoter region,
like the previously identified miR-M2 to miR-M5 miRNAs,
suggesting that these six miRNAs are part of the same tran-
scriptional unit in the same transcriptional orientation as Meq.
The high levels of expression of all six of these miRNAs,
demonstrated by strong signals in Northern blotting of RNAs
from MSB-1 and tumor cells (Fig. 3), suggest that these miRNAs
may have major roles in regulating the expression of viral and
host genes in latently infected/transformed T cells. The tran-
scription unit of these miRNAs is also antisense to another
potential transcript, RLORF8, demonstrated in both CEF and
lymphoblastoid cells (52), and hence has the potential to reg-
ulate the expression of RLORF8. A recent study demonstrated
that EBV-encoded miR-BART2 can downregulate the viral
DNA polymerase BALF5 via a similar mechanism (4). How-
ever, unlike miR-M2 and miR-M4, which are embedded in the
RLORF8 ORF, the newly identified miRNAs miR-M9 and
miR-M12 are located downstream of the ORF (Fig. 2).
One of the previously identified miRNAs, miR-M1, mapped
downstream of Meq embedded in the ORF of the L1/
RLORF5a transcript, although it is not clear whether it affects
the expression of this transcript (33, 46, 59). We have identified
a new miRNA, mdv-miR-M11, located just downstream of the
Meq ORF (Fig. 2). The importance of this novel miRNA is not
known, but it is expressed at only very low levels, as indicated
by a low cloning frequency in the library and weak signals in
Northern blot analysis.
In addition to the three miRNAs, miR-M6 to -M8, that
mapped to the LAT region, our studies have revealed miR-
M10 and miR-M13, two novel miRNAs encoded from this
region. Because these miRNAs are located very close to
miR-M6 to -M8 and are in the same transcriptional orienta-
tion, these two miRNAs are highly likely to be part of the same
cluster. However, compared to miR-M6 to -M8, which are
expressed at very high levels (Table 2 and Fig. 3), the levels of
expression of miR-M10 and miR-M13, shown by Northern
blotting and cloning frequencies, are very low. Although the
reasons for their low expression levels are not known, the
efficiency in processing of the mature miRNAs could be a
factor, especially because of their close proximity within the
cluster. For example, miR-M13 is located between the highly
expressed miR-M6 and miR-M8 miRNAs, with the mature
miRNA sequence of miR-M6 being separated from that of
miR-M13 by only a single nucleotide (Table 2). Similarly, the
newly identified miR-M10 (only 6 hits in the library) is located
just adjacent to the most highly expressed miRNA, miR-M7,
which had 800 hits in the library.
Although the expression levels of MDV-1-encoded miRNAs
in MSB-1 cells were generally similar to those in tumor tissues,
there were clear differences in expression level between in-
fected CEF and transformed MSB-1 cells, with the latter gen-
erally expressing higher levels of all miRNAs. However, it was
also interesting to see clear differences between miRNAs in
the specificity of the strand expressed in infected CEF and
MSB-1 cells. The most striking example of strand-specific ex-
pression was noted for miR-M7, where the mature miRNA
strand, miR-M7-5p, had 800 hits, accounting for 16% of the
entire MSB-1 library. Northern blot analysis also revealed very
strong expression of this miRNA in both MSB-1 cells and
tumor tissues. Although weak signals for miR-M7-5p were
detected in the infected CEF, this strand was not identified
even once among the nearly 172,000 high-quality reads of small
RNA sequences from infected CEF (9), suggesting that this
miRNA strand is processed only at very low levels in lytically
infected CEF. This cluster of miRNAs maps antisense to the
ICP4 gene and to the large intron in the 5 end of the putative
LAT, expressed at high levels in transformed cells/lymphomas
as well as in the late stages of lytic infection of CEF (57).
Although the reasons for the differences in processing of the
two miRNA strands during miRNA biogenesis in this region
between CEF and lymphocytes are not clear, it would be in-
teresting to see whether any of the miRNAs play a role in
switching between lytic replication and latency. Intriguingly,
mdv-miR-M7 also showed evidence of RNA editing. However,
FIG. 4. Pie chart showing proportions of MDV-1, MDV-2, and chicken miRNAs and other molecules cloned from the MSB-1 library.
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in the absence of knowledge on the targets of any of the
MDV-1-encoded miRNAs, the significance of this remains un-
known.
Analysis of the miRNA repertoire from MSB-1 cells also
identified several host miRNAs, some of which were cloned at
high frequencies indicating high levels of expression (Table 1).
Some of the more abundant host miRNAs, such as those
within the miR-17-92 cluster, have been shown to be amplified
in several types of cancer (28, 29). Since these miRNAs have
been shown to accelerate the formation of lymphoid malignan-
cies in mouse models (29), the increased expression of these
miRNAs in MSB-1 cells could be significant. Similarly, other
highly expressed miRNAs, such as miR-21 (249 hits), let-7i
(148 hits), the two strands of miR-142 (224 and 243 hits),
miR-15a (28 hits), and miR-16 (82 hits), have also been asso-
ciated with various malignancies, including chronic lympho-
cytic leukemia (12, 18), suggesting that these miRNAs may
contribute toward MDV oncogenicity. Currently, we are ex-
amining the roles of different host miRNAs in the induction of
lymphomas by MDV. Our studies on MSB-1 cells also revealed
six novel chicken miRNAs. The expression of five of these
novel miRNAs could be detected by Northern blotting of dif-
ferent chicken tissues, although the expression of miR-454 in
all tissues was very weak (Fig. 3b). The expression of both
strands of miR-142 appeared to be restricted to the lympho-
cyte-enriched lungs, thymus, and spleen (Fig. 3b), suggesting
that it is likely to be a lymphoid cell-specific miRNA.
We have carried out a study to examine the miRNAome of
a herpesvirus-induced lymphoma in chickens by determining
the miRNAs expressed in a lymphoblastoid cell line derived
from a lymphoma. This study is the first of its kind with an
avian lymphoma and has demonstrated that the analysis of the
miRNA repertoire would enable investigation of some of the
potential pathways used by viruses in neoplastic transforma-
tion. A major challenge in the next stage would be the identi-
fication of potential targets for some of the miRNAs overex-
pressed in these cells to identify networks of molecular events
regulated by the altered miRNAome in these cells. The
present study has not identified miRNAs that are downregu-
lated in transformed cells, whose profiles are also very impor-
tant for understanding the global events involved in transfor-
mation. Currently, we are using microarray analysis of global
viral/host miRNA expression in MD tumor cells in relation to
that in normal lymphocytes to determine the entire repertoire
of upregulated and downregulated miRNAs to identify the
extent to which MDV exploits the cellular miRNA pathways to
induce neoplastic transformation.
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